Opportunistic infections, such as aspergillosis, are among the most serious complications suffered by immunocompromised patients. Aspergillus fumigatus and other pathogenic fungi synthesize a toxic epipolythiodioxopiperazine metabolite called gliotoxin. Gliotoxin exhibits profound immunosuppressive activity in vivo. It induces apoptosis in thymocytes, splenocytes, and mesenteric lymph node cells and can selectively deplete bone marrow of mature lymphocytes. The molecular mechanism by which gliotoxin exerts these effects remains unknown. Here, we report that nanomolar concentrations of gliotoxin inhibited the activation of transcription factor NF-~B in response to a variety of stimuli in T and B cells. The effect ofgliotoxin was specific because, at the same concentrations, the toxin did not affect activation of the transcription factor NF-AT or of interferon-responsive signal transducers and activators of transcription. Likewise, the activity of the constitutively DNA-binding transcription factors Oct-1 and cyclic AMP response element binding protein (CREB), as well as the activation of protein tyrosine kinases p56 lck and p59 fyn, was not altered by gliotoxin. Very high concentrations of gliotoxin prevented NF-~B DNA binding in vitro. However, in intact cells, inhibition of NF-~13 did not occur at the level of DNA binding; rather, the toxin appeared to prevent degradation of IKB-ci, NF-KB's inhibitory subunit. Our data raise the possibility that the immunosuppression observed during aspergillosis results in part from gliotoxin-mediated NF-KB inhibition.
B
ecause of the development of intensive combination chemotherapy and bone marrow transplant preparatory regimens, both of which cause prolonged myelosuppression, the incidence of fungal infections in cancer patients has risen sharply in the past decades (1) . Fungal infections are now the cause of death in 40% of patients with acute leukemia at some hospitals. In a recent international survey (2) , 30% of mycotic infections represented cases ofaspergillosis, which is caused by the fungi Aspergillusfumigatus, A. flavus, A. niger, and A. terreus. Aspergillosis carries a very high mortality rate, survival ranging only between 5 and 20%.
The precise molecular mechanism of Aspergillus pathogenesis remains unclear. One possible etiological agent is the secondary fungal metabolite gliotoxin. This metabolite is produced in large quantifies by fungal cultures and can be isolated from mice undergoing systemic experimental aspergillosis (3) . Gliotoxin belongs to the epipolythiodioxopiperazine class of compounds and is lethal at relatively low concentrations (LDs0 in mice and rats: 25-50 mg/kg) (4) . Gliotoxin exhibits profound immunosuppressive effects in vivo. Sublethally irradiated mice injected intraperitoneally with gliotoxin showed a significant delay in the recovery of immune cells compared with untreated irradiated controls (5) . Whereas LPS-responsive B cells were detected by proliferation assays in control animals 14 d after irradiation, animals treated with a single dose of 100 Ftg gliotoxin showed no measurable B cell response until 30 d after irradiation. By contrast, the recovery of the T cell response, as measured by Con A-stimulated cell proliferation, was equal in both mock-and gliotoxin-treated animals. The in vivo data differ somewhat from observations in vitro, where gliotoxin inhibits mitogen-induced proliferation of both B and T cells. Furthermore, in MLCs, pretreatment ofstimu-lator cells with gliotoxin completely abrogates the induction of alloreactive cytotoxic T cells (6) . When low concentrations (100 ng/ml) ofgliotoxin are used, this inhibition can be overcome by the addition of IL-2. However, at higher concentrations of gliotoxin, T cell activation is suppressed even in the presence of cytokines. In addition to the inhibition of lymphocyte stimulation and proliferation, gliotoxin also induces apoptosis in these cells as well as in macrophages, L929 fibroblasts, and squamous carcinoma cells in vitro (7) (8) (9) . In vivo, gliotoxin induces apoptosis in thymocytes, spleen cells, and cells of the mesenteric lymph nodes (5) .
Gliotoxin exerts its immunosuppressive effects in part by inhibiting activation and proliferation of B and T cells. We therefore investigated whether the toxin interferes with the activation of transcription factors that are crucially involved in B and T cell activation and proliferation: nuclear factor (NF-KB1/Ikel), nuclear factor of activated T cells (NF-AT), and signal transducer and activator of transcription (STAT) factors. NF-KB is a central mediator of the immune response (10) . It regulates the transcription of various inflammatory cytokines, hematopoetic growth factors, growth factor receptors, and cell adhesion molecules (listed in detail in reference 10). In most cell types, NF-KB is sequestered in an inactive, cytoplasmic complex by binding to IKB, its inhibitory subunit (11) . A large variety ofT or B cell-activating stimuli rapidly induce NF-KB, stimulating ~B-dependent transcription. Many NF-KB target genes encode proteins controlling cell proliferation. NF-mB activation requires phosphorylation and proteolytic degradation of IKB subunits (12) (13) (14) (15) (16) . The active NF-KB complex, which translocates to the nucleus, is frequently composed of a heterodimer of p50 and P, elA (p65) subunits (17) . Whereas mouse null mutants of p50 are viable and show only a very weak immunodeficient phenotype (18) , null mutants of R.elA die in utero and show massive apoptosis in the liver (19) . Mice lacking c-tel are defective in lymphocyte proliferation, humoral immunity, and IL-2 expression (20) . Pharmacological inhibition of NF-Jd3 in vivo may thus affect immune regulation as well as cell survival.
The NF-AT family of transcription factors, whose members share weak sequence similarity with NF-mB/Rel proteins, also plays an important role in T cell activation. These proteins regulate the expression of the genes for IL-2, -3,-4, GM-CSF, and TNF-ot (21) . Activation of cytoplasmic NF-AT factors requires the calcium-and calmodulin-dependent phosphatase calcineurin, nuclear translocation of NF-AT, and the association of NF-AT with an AP-1 factor on the DNA (for reviews see references 22, 23) . The importance of NF-AT in T cell activation is illus1Abbreviations used in this paper: CR.EB, cyclic AMP response element binding protein; DTT, dithiothreitol; EMSA, electrophoretic mobility shift assay; ICAM-1, intercellular adhesion molecule 1; IlkF, interferon regulatory factor; ISGF3, IFN-stimulated gene factor 3; ISRE, IFN-stimulated response element; LIF, leukemia inhibitory factor; NF-AT, nuclear factor of activated T cells; NF-Y,B, nuclear factor KB; STAT, signal transducer and activator of transcription.
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Gliotoxin Inhibits NF-KB trated by the effect of the fungal metabolites cyclosporin A and FK506. These agents indirectly inhibit calcineurin thereby preventing NF-AT activation (24, 25) . Treatment of patients with cyclosporin A or FK506 causes a potent immunosuppression that is exploited clinically for organ transplantation (26--28) . Natural immunosuppressive compounds with specificity for NF-mB have not yet been reported. Stimulation of cells in response to IFNs is mediated by the STAT family of transcription factors. Like NF-AT and NF-mB/R.el proteins, STATs are maintained in a cytoplasmic form in unstimulated cells (29) . STAT activation occurs via direct phosphorylation by receptor-associated tyrosine kinases, subsequent dimerization via SH2 domains, and nuclear translocation (30) . Stimulation of cells with type I IFN (IFN-Ix/13) causes activation of STAT1 and STAT2, which subsequently form a transcription factor, ISGF3, which consists ofa STAT1-STAT2 heterodimer in association with a 48-kD DNA-binding protein. This 48-kD subunit belongs to the IR.F family of proteins (30) . ISGF3 activates transcription of target genes like MHC class I by associating with a promoter DNA sequence designated the interferon-stimulated response element (ISRE). In contrast, type II IFN (IFN-~/) exclusively activates STAT1 so that a homodimer is formed that binds to a distinct response element, the gamma interferon activation site (GAS; 30). Other cytokines and growth factors, including prolactin, epidermal growth factor, IL-2, -3, -4, -6, -12, LIF, erythropoietin, and growth hormone also use members of the STAT factor family as signal transducers (31) (32) (33) (34) (35) (36) .
We show here that nanomolar concentrations of gliotoxin specifically inhibited the activation of NF-KB in various cell types, whereas the activation of NF-AT and STAT factors was not affected at such low concentrations. The toxin prevented stimulation of KB-controlled reporter gene activity by TNF, IL-1, and PMA whereas it did not affect induction in response to IFN-~/. NF-KB activation in response to five different stimuli (LPS, IL-I[~, TNF-(x, PMA/PHA, and okadaic acid) was blocked, suggesting that gliotoxin interfered with a late step in a common signaling cascade leading to NF-v,B activation. Very high concentrations of gliotoxin inhibited NF-KB DNA binding in vitro, most likely because of oxidation of a cysteine residue by the toxin's sulthydryl group. However, this modification did not occur in vivo: overexpressed p50 and cytoplasmic NF-KB complexed with IKB were not inactivated by the toxin. Inhibition of NF-~B activation most likely results from inhibition of IKB-ot proteolysis. Our data suggest that the immunosuppressive activity of the fungal metabolite gliotoxin may rely on inhibition of the transcription factor NF-KB in T and B cells.
Materials and Methods

Cell Culture
Jurkat, 70Z/3, D10.G4.1, and stably transfected A549 ceUs were maintained in 1LPMI 1640 medium; HeLa $3 and 293 ceils were maintained in DMEM. Both were supplemented with 10% FCS and 50 p~g/ml penicillin-streptomycin (all from GIBCO BILL, Eggenstein, Germany). Medium for D10.G4.1 cells contained 50 ~g/ml [3-ME and 50 U/ml IL-2 in addition. The 70Z/3 cells transfected with the p55 TNF receptor were generously given by Dr. M. Kr6nke (Kiel, Germany); gliotoxin, methylthiogliotoxin (bis-dethio-bis(methylthio)-gliotoxin), P/VIA, and LPS were purchased from Sigma Chemical Co. (Miinich, Germany). Other chemicals were obtained from the following supphers: okadaic acid (Paesel and Lorei GmbH & Co., Hanan, Germany), IL-l[3 (Genzyme Corp., Cambridge, MA) and TNF (Boehringer-Mannheim, Mannheim, Germany).
Transfections
293 cells were plated 12-16 h before transfection at a density of 106 cells per 60-mm dish. Transfections were performed using calcium phosphate precipitation as previously described (16) .
Transactivation Assays
A549 cells, stably transfected with the plasmid pGLH3 carrying a hiciferase reporter gene driven by a fragment of the intercellular adhesion molecule (ICAM) 1 promoter (bp -277 to -9 relative to the start of transcription) carrying response elements for both TNF-a and IFN-~/ (37-39), were seeded in microtiter plates. Cells were pretreated with either 1 Ixg/ml gliotoxin or 3 I.tg/ml bis-dithio-bis(methylthio)-gliotoxin for 30 rain before stimulation with either 300 U/ml TNF-ot, 1 ng/ml IL-I~, 20 ng/ml PMA, or 300 U/ml IFN-~/ for 6 h. Cells were harvested in situ using a commercial lysis buffer and luciferase assay system (Promega Corp., Heidelberg, Germany) and luciferase activity was determined on a microplate scintillation counter (TopCount; Packard Instruments Co., Inc., Meriden, CT).
Plasmids
The expression vector containing amino acids 1-399 of the NF-KB p50 subunit has been previously described in detail (40) .
Electrophoretic Mobility Shift Assays
NF-KB, Oct-l, and CREB. Total cell extracts were prepared using a high salt detergent buffer (Totex buffer) (20 mM Hepes, pH 7.9, 350 mM NaC1, 20% (vol/vol) glycerol, 1% (wt/vol) NP-40, 1 mM MgC12, 0.5 mM EDTA, 0.1 mM EGTA, 0.5 mM dithiothreitol [DTT], 0.1% PMSF, and 1% aprotinin). Cells were harvested by centrifugation, washed once in ice-cold PBS (Sigma) and resuspended in four cell volumes of Totex buffer. The cell lysate was incubated on ice for 30 min, then centrifuged for 5 min at 13,000g at 4~ The protein content of the supernatant was determined and equal amounts of protein (10-20 ~,g) were added to a reaction mixture containing 20 btg BSA (Sigma), 2 ~g poly (dl-dC) (Boehringer Mannheim), 2 ~1 buffer D + (20 mM Hepes, pH 7.9, 20% glycerol, 100 mM KCI, 0.5 mM EDTA, 0.25% NP-40, 2 mM DTT, and 0.1% PMSF), 4 btl buffer F (20% Ficoll-400, 100 mM Hepes, 300 mM KC1, 10 mM DTT, 0.1% PMSF), and 100,000 cpm (Cerenkov Counting) of a 32p-labeled ohgonucleotide in a final volume of 20 btl. Samples were incubated at room temperature for 25 rain. NF-JcB, CREB, and Oct-1 ohgonucleotides (Promega) were labeled using ~/-[32p]ATP (3,000 Ci/mmol; Amersham International, Braunschweig, Germany) and T4 polynucleotide kinase (Promega).
DOC Activation. DOC activation was performed precisely as 1831
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previously described (11); the detergent (purchased from Sigma) was added to a final concentration of 0.4%.
NFoAT. Nuclear extracts were prepared as previously described (41) . Electrophoretic mobility shift assay (EMSA)-binding reactions were identical to those used for NF-rd3, Oct-l, and CREB except that only 0.2 ~g/ml poly (dl-dC) was used.
S TAT Factors
ISGF3 activation was determined in an EMSA using the ISRE from the promoter of the ISG15 gene (42) as a probe. HeLa $3 cells were treated for 12 h with 1 ng/ml IFN-~ followed by a 30-min stimulation with 1,000 U/ml of IFN-el before harvest. Where indicated, gliotoxin was added 30 min before addition of IFN-e~ and remained in the culture medium during IFN stimulation. The EMSA conditions have been described previously (29) . For in vitro treatment of ISGF3 with gliotoxin, the extracts were treated with the indicated concentrations of the drug for 30 min at room temperature before addition to the EMSA-binding reaction.
Immunoprecipitation and Kinase Assays
Jurkat cells (2 • 10 v) were pretreated with different concentrations ofgliotoxin for 1 h and subsequently stimulated with 50 ng/ ml PMA for 30 min. Cells were washed with ice-cold PBS containing 400 ~M EDTA and 400 I~M sodium vanadate and lysed in 250 ~1 of RIPA buffer (5 mM EDTA, 150 mM NaC1, 0.1% SDS, 1% Triton X-100, 100 ~,M Na3VO4, 1 mM DTT, 1 mM PMSF, 10 ~g/ml leupeptin, and 10 mM sodium phosphate, pH 7.4). Nuclei and cell debris were removed by centrifugation at 16,000 g for 15 rain at 4~ The supematant was precleared with protein A-Sepharose (Pharmacia LKB, Freiburg, Germany) and immunoprecipitated with 1 ~g of rabbit anti-p56 ]ck or anti-p59 cy" antibody (Upstate Biotechnology, Inc., Lake Placid, NY). Immune complexes were collected with protein A-Sepharose and washed twice with lysis buffer, once with 10 mM Hepes, pH 8.0, containing 50 mM NaC1, and once with Hepes buffer without NaC1. Immune complex kinase assays were performed by incubation at 25~ in 50 I~1 kinase buffer (30 mM Hepes, pH 7.2, 5 mM MgC12, 5 mM MnC12, 1 ~M ATP, and 10 btCi ~-[32p]ATP) containing 5 ~g of acid-treated rabbit muscle enolase (Sigma). After 15 min, the reaction was ended by the addition of Laemmli buffer. The samples were analyzed by 10% SDS-PAGE and subjected to autoradiography.
Western Blotting
Total cell extracts (100 ~g) were boiled in Laemmli sample buffer and subjected to SDS-PAGE. Before transfer, gels were equilibrated in ice-cold blotting buffer (48 mM Tris, 39 mM glycine, 15% methanol, and 0.037% SDS). Proteins were transferred at 2.5 mA/cm 2 for 1 h onto Immobilon P membranes (Millipore Corp., Eschborn, Germany) using a semi-dry blotting apparatus (Bio-Rad Laboratories, Miinich, Germany). Transfer efficiency was monitored by Ponceau S staining of membranes. Nonspecific binding sites were blocked by immersing the membrane in TBST blocking solution (10 mM Tris-HC1, pH 8.0, 150 mM NaC1, 0.1% Tween 20 [vol/vol]) containing 5% low-fat dried milk powder) overnight at 4~ After a short wash in TBST, the membranes were incubated in a 1:700 dilution of anti-Ivd3-oe antibody (12) in blocking solution for 1 h at room temperature, followed by extensive washing with TBST. Bound antibody was decorated with goat anti-rabbit/horseradish peroxidase conjugate (BioRad; diluted 1:3,000 in blocking solution) for 30 rain at room temperature. After washing for 45 nain, the immunocomplexes were detected using enhanced chemiluminescence Western blotting reagents (ECL; Amersham). Exposure to Eastman Kodak X A R -5 film (Rochester, NY) was performed for 30 s. for 1 h. Subsequently, cells were stimulated for 1 h with PMA/PHA, after which total cell extracts were prepared. The extracts were analyzed for NF-~B DNA-binding activity in an EMSA. Stimulation with P M A / P H A induced one novel DNA-binding activity in Jurkat T cells (Fig. 1 A,  lane 2) . Antibody reactivity and competition assays identified this complex as a NF-v,B p50/p65 heterodimer (data not shown; 15, 43). NF-KB activation was significantly reduced by treatment of Jurkat cells with 70 ng/ml of gliotoxin, whereas 100 ng/ml (300 nM) gliotoxin and higher concentrations completely prevented NF-v,B induction ( Fig. 1 A,  lanes 7 and 8) . The weak basal activity of NF-KB (lane 1) was not reduced even at very high gliotoxin concentrations (lanes 10-14) , indicating that the toxin did not directly inhibit NF-KB D N A binding. A very similar dose-response was observed in the HeLa tumor cell line as well as in various other cell lines (see below; data not shown). A faster migrating, nonspecific DNA-binding activity was not altered by gliotoxin treatment, even when doses <~50 ~g/ml were used ( Fig. 1 A, lane 14) .
Results
Gliotoxin Is a Potent Inhibitor of NF-~B Activation. T o investigate w h e t h e r gliotoxin interferes w i t h the activation o f transcription factors i n v o l v e d in T cell activation, J u r k a t T cells were i n c u b a t e d w i t h various concentrations o f g l i o t o x i n
We analyzed the Jurkat T cell extracts shown in Fig. 1 A in EMSAs using D N A probes containing consensus motifs for the constitutively bound transcription factors Oct and CREB (Fig. 1 B) . Treatment with gliotoxin concentrations 4 5 0 ~g/ml did not detectably affect D N A binding of Oct and CREB proteins to their respective D N A probes. Taken together, these data show that treatment of cells with gliotoxin at nanomolar concentrations specifically inhibits the activation of transcription factor NF-v,_B, whereas the DNA-binding activity of other transcription factors remained unaffected at up to 500-fold higher concentrations.
Gliotoxin Is an Inhibitor of NF-KB-dependent Gene Expression. The inducible expression of the ICAM-1 gene in response to TNF-cx, IL-113, and PMA is controlled by a NF-v,B-binding site in its upstream promoter, whereas the inducibility in response to IFN-~/is controlled by a binding motif for STAT1 (37) (38) (39) . Here, we tested the effect of gliotoxin on the expression of a stably integrated firefly luciferase reporter gene under control of a fragment of the human ICAM-1 promoter in A549 cells (37) . As shown in Fig. 2 , TNF-o~, IL-I[~, PMA, and IFN-~/caused a substantial induction of the reporter gene. 1 ~g/ml gliotoxin, which did not affect the basal ICAM-1 promoter activity, suppressed reporter gene induction by TNF-o~, IL-I[~, and PMA, which act via the v,B motif. By contrast, gliotoxin could not suppress induction of the ICAM-1 promoter by IFN-% which is mediated by STAT transcription factors. These data provide compelling evidence for the specificity of the toxin. The inhibitory activity of gliotoxin on KBdependent gene expression relied on intact sulfhydryl groups; 3 ~g/ml of the immunologically inactive derivative methylthiogliotoxin (44, 45) did not display any inhibitory potential (Fig. 2) . At higher concentrations ofgliotoxin, inhibitory as well as stimulatory effects on the activity of var- Figure 2 . The effect of gliotoxin on ICAM-I promoter-driven reporter gene activity. A549 cells stably transfected with a luciferase reporter gene driven by a fragment of the ICAM-1 promoter were treated for 30 rain with either 1 ~g/ml gliotoxin or 3 ~g/ml methyl gliotoxin as indicated. Subsequently, cells were induced with either 300 U/ml TNF-~, 1 ng/ml IL-113, 20 ng/ml PMA, or 300 U/ml IFN-~/for 6 h and luciferase activity was determined. The results are given in arbitrary relative light units and are representative of three experiments.
ious unrelated promoters and enhancers were observed in reporter gene assays (data not shown), suggesting that only low concentrations o f gliotoxin specifically affected N Fr Functional analysis o f the ICAM-1 promoter thus corroborates data obtained from EMSAs showing that nanomolar concentrations o f gliotoxin potently and specifically inhibit NF-Kt3 activation.
Gliotoxin Does Not Impair Activation of STA T and NF-A T Factors.
To further investigate the specificity ofgliotoxin, we studied the activation o f STAT and N F -A T factors by IFNs and P M A / i o n o m y c i n , respectively. The effect o f gliotoxin on the activation o f S T A T factors was tested in HeLa $3 cells. In these cells, NF-KB activation is also inhibited by pretreatment with 100 n g / m l of gliotoxin (data not shown). Extracts from control or IFN-(x/~/--stimulated cells were assayed in an E M S A using an ISRE as the D N A probe (Fig.  3 A) . binding to a GAS sequence in the IRF1 promoter (47), these conditions also determine whether STAT1 homodimer activation is intact. Doses o f ~<10 i~g/ml gliotoxin did not significantly perturb the activation o f STAT1, STAT2, IRF-2, and p48 in response to IFN-tx/~ stimulation of HeLa $3 cells (Fig. 3 A, lanes 4-7) . Similarly, treatment of extracts from IFN-ot/~/-stimulated HeLa $3 cells with gliotoxin under cell-flee conditions had no effect on the D N A -b i n d i n g o f these factors (Fig. 3 B) . D 10.G4.1 T cells behaved similarly to Jurkat T cells with respect to the inhibition of NF-KB activation by gliotoxin (data not shown). In nuclear extracts o f these cells, treatment with P M A / i o n o m y c i n strongly induced an activity that binds to the distal N F -A T site in the murine IL-2 enhancer (Fig. 4, compare lanes 1 and 2) . This p r o t e i n -D N A complex is specifically competed by an excess o f unlabeled oligonucleotide (data not shown). T cells were treated for 1 h with increasing concentrations o f gliotoxin followed by a 1-h stimulation with P M A / i o n o m y c i n . Activation of N F -A T from its cytoplasmic form was not affected by a treatment o f D10.G4.1 T cells with gliotoxin, even at a concentration of 10 Ixg/ml, 100-fold the concentration that abbrogated activation o f NF-KB (see Fig. 1 ). As seen in previous experiments (Figs. 1-3) , none of the unrelated nonspecific DNA-binding activities was sensitive towards gliotoxin. Taken together, these data show that treatment of cells with gliotoxin specifically inhibits the activation of transcription factor NF-gB whereas other constitutive and inducible factors remain unaffected at up to 500-fold higher concentrations. In the following, we examined several steps in the signal transduction pathway, which lead to NF-r,B activation in B and T cells, for their susceptibility to gliotoxin.
Gliotoxin Acts on a Common Mechanism of NF-KB Activation. NF-r,B can be activated by numerous stimuh (10) . Reporter gene assays using the ICAM-1 promoter (Fig. 2) showed that gliotoxin inhibits NF-r,B activation in response to several different stimuli, suggesting that the toxin targets a signal transduction step shared by many inducers. To test this hypotesis, we used the pre-B cell line 70Z/3, in which NF-r,B can be activated by such diverse stimuh as PMA, LPS, IL-1~3, or the phosphatase 2A inhibitor okadaic Pahl et al.
acid. In a stably transfected 70Z/3 clone carrying the p55 TNF receptor (48) , NF-r,B can also be induced with TNF-et. 70Z/3 or 70Z/3-p55 cells were preincubated with 1 p,g/ml of gliotoxin for 1 h before stimulation with the various NF-r,B inducers. The stimuli induced NF-gB DNA-binding activity to different levels (Fig. 5) . Pretreatmerit with gliotoxin completely prevented the activation of NF-r,B by all five stimuli, indicating that the toxin interfered with a common event shared by all inducers.
Only Very High Concentrations of Gliotoxin Inactivate NF-KB D N A Binding. A simple explanation for the inhibitory effect of gliotoxin would be a direct interference with the DNA-binding assay detecting NF-,<B. Gliotoxin is a sulfhydryl compound with the potential to covalently modify proteins by formation of mixed disulfides with exposed cysteine residues (3). NF-r,B subunits harbor a redox-sensitive cysteine residue in their DNA-binding domains (49) (50) (51) . In addition, gliotoxin has been shown to cause DNA breaks at 90 p,g/ml in vitro (52) , such that high gliotoxin concentrations may impair DNA-binding reactions by damaging the oligonucleotide probe. To test these possibilities, we incubated cell extracts from PMA/PHA-activated Jurkat T cells containing activated NF-gB with gliotoxin. Addition of 25 p,g/ml gliotoxin to the DNA-binding reaction did not detectably inhibit NF-gB DNA binding in vitro (Fig. 6, lane 3) . Only concentrations I>250 p,g/ml impaired DNA binding of NF-gB (Fig. 6, lanes 4 and 5) .
It is possible that in intact cells gliotoxin is converted into a metabolite that directly modifies NF-KB. We investigated this hypothesis by transfecting 293 cells with an expression vector for the p50 DNA-binding subunit of NF-gB. p50 was previously shown to be highly susceptible to modification of Cys62 by oxidants (49, 51) . Overexpressed p50
is not subject to significant IgB inactivation and will therefore constitutively bind DNA as a homodimer (53) . Transfected 293 cells expressing p50 NF-,<B were treated with increasing concentrations of gliotoxin for 2 h after which cell extracts were analyzed by EMSA. Concentrations of 450 p,g/ml gliotoxin, 500-fold the inhibitory dose for NF-gB activation, did not impair the p50 DNA-binding activity in vivo (Fig. 7) . In addition, we found that the NF-r,B/I,<B complex in nonstimulated 70Z/3 pre-B cells, was not inactivated by gliotoxin treatment; deoxycholate treatment (11) recovered similar amounts of NF-r,B activity in cell extracts from control and gliotoxin-treated cells (Fig. 8, compare lanes 2 and 4) . Taken together, these data suggest that gliotoxin does not directly modify NF-KB DNA-binding subunits in vivo.
Gliotoxin Does Not Prevent Activation of Tyrosine Kinases p56 ~k or p59~" upon T Cell Activation. An early event after stimulation of the T C R is the activation of the Src-hke tyrosine kinases p56 lck and p59@" (54, 55) . Extracts from control and gliotoxin-treated Jurkat T cells were used for immunoprecipitation with antibodies against p56 lck or p59 fy". Kinase activities were determined by incubation of immunoprecipitates with the substrate rabbit muscle enolase and ~-[32p]ATP. Tyrosine-phosphorylated enolase was then separated by SDS-PAGE and visualized by autoradiography ( Fig. 9) . Stimulation o f Jurkat cells with P M A resulted in 8.8-and 6.7-fold induction o f enolase phoshorylation by p56 lck and p59 ~yn immunoprecipitates, respectively (data not shown). T r e a t m e n t o f J u r k a t T cells with gliotoxin c o n c e ntrations ~<10 w g / m l did not detectably affect the ability o f either p56 lck or p59 fyr' to phosphorylate rabbit muscle e n olase (Fig. 9) , suggesting that gliotoxin did not prevent N F -KB activation by inhibiting TC1K-associated tyrosine kinases. Ir, B is readily detected in Western blots as a slight decrease in protein mobility. Jurkat T ceils were treated with gliotoxin for 1 h and stimulated with 0.5 btM okadaic acid for 60 min. IKB-oe was detected on Western blots using a polyclonal antibody (12) . In control cells, okadaic acid stimulation led to both a decreased mobility of IKB-Ix and a reduction in the total amount o f ImB (Fig. 10, top, lane 2) , which coincided with NF-KB activation in EMSAs (bottom, lane 2). In gliotoxin-treated cells, the inducible mobility decrease of IgB-ot in response to okadaic acid is still observed (Fig. 10, top, lane 4) , indicating that the toxin did not inhibit the IKB-o~ kinase. However, more phosphorylated IKB-ci was present and, consequently, less NF-mB activated (Fig. 10, bottom, lane 4) than under control conditions (compare lanes 2 and 4), suggesting that gliotoxin interfered with IKB-ot degradation.
Gliotoxin Allows IKB-oe Phosphorylation but Prevents Its
Discussion
Invasive aspergillosis represents one of the most diflficult therapeutic problems in immunocompromised patients. De- (3) . To date, however, gliotoxin has not been implicated directly in the pathogenesis of aspergillosis and its mechanism of action remains a matter o f debate (57, 58) .
W e show here that gliotoxin inhibits the activation of transcription factor NF-r,B, a central mediator o f the human immune reponse. NF-KB activates the transcription of various cytokine genes including those for IL-1, IL-2, G M -CSF, G-CSF, M -C S F , and IL-6 (10). Gliotoxin inhibits Figure 9 . The effect of gliotoxin on the activity of p56 kk and p59 fyn. Jurkat cells were treated with various concentrations of gliotoxin as indicated for 1 h before stimulation with 50 ng/ml PMA for 10 min. CeU extracts were imrnunoprecipitated with antibodies against the kinases p56 l& and p59 ~yn. Precipitated proteins were incubated with rabbit muscle enolase and ~/-[32p]ATP for 15 min after which the reaction products were analyzed by SDS-PAGE.
IL-1 synthesis in macrophages and the release of IL-2 from activated T cells (6, 59) . These effects can now be explained by the inhibition of NF-KI3 activation. Similarly, gliotoxin treatment of stimulator cells prevents the induction of alloreactive cytotoxic T cells in MLCs. This most hkely results from the loss of NF-KB-mediated IL-2 expression (60) , since the inhibition can be overcome by the exogenous addition oflL-2. Gliotoxin's inhibition ofmitogen-activated T and B cell proliferation (45) may also be a consequence of NF-~I3 inhibition: NF-KB is induced by many B and T cell mitogens such as LPS, Con A, anti-CD28, anti-CD3, anti-IgM, and lymphotrophic viruses (10) . By inhibiting NF-~O3 activation, gliotoxin may interrupt one signal transduction pathway leading to T and B cell proliferation. The selective delay in the recovery of LPS-reponsive B cells in gliotoxin-treated mice (5) can be explained in the same manner.
The mechanism of action by which gliotoxin exerts its effect remains a matter of debate. It has been shown that gliotoxin causes DNA fragmentation in vitro and in vivo. In vivo, treatment of L929 fibroblasts, a sheep squamous cell carcinoma hne, macrophages, or spleen cells with 30 ng-1 I~g/ml of gliotoxin for 1 h causes DNA fragmentation (9) . Other cell types, for example the monkey kidney cell line Vero, the rat mammary carcinoma MAT, or the mouse mastocytoma cell hne P815 are resistant to gliotoxin-induced DNA damage. In vitro, gliotoxin shows no effect on DNA on its own; high concentrations of the toxin (0.3 mM or 90 p,g/ml) need to be incubated with reductants such as DTT or glutathione in order to produce DNA damage (52) .
Eichner et al. (52) proposed that the DNA damage is caused by the production ofH20 2 through redox-cycling of gliotoxin. In this model, gliotoxin undergoes intracellular processing to the dithiol derivative, generating a redox cycle that produces superoxide anions and ultimately, H20 2. This hypothesis has been contradicted by Schweizer and Richter (57) , who find no evidence for either redoxcycling or H20 2 production by gliotoxin in isolated mitochondria. Rather, they propose that gliotoxin reacts with thiol groups to cause a transient release of Ca 2+ from mitochondria. Contrary to this report, Beaver and Waring (58) found no increase in intracellular Ca 2+ levels when thymocytes were treated with concentrations of gliotoxin between 50 nM and 10 ~M. Only doses >500 mM produced large increases in intracellular Ca 2+ levels.
Based on the data presented in this paper, we propose a new model for the mechanism of action of ghotoxin. We suggest that gliotoxin's effects on immune cells are mainly due to the inhibition of NF-~13 activation. An inability to activate NF-KB is also achieved in transgenic mice, which carry a deletion in the gene for the p65 subunit of NF-KB. These animals die in utero and show severe apoptosis in the liver (19) . It is interesting to note that mice treated with gliotoxin show extensive apoptosis in spleen cells by light and electron microscopy and by DNA fragmentation analysis (5) . Both the fetal hver and the adult spleen are hematopoietic organs. Perhaps certain hematopoietic cells require the abihty to activate NF-KB in order to avoid programmed cell death. Spleens from gliotoxin-treated mice are selectively depleted of B cells (5) . FACS | analysis performed 16 d after gliotoxin treatment identified 37% of the splenocytes as B cells whereas in control animals, 70% of the population were stained with a B cell marker. It appears that the inability to activate NF-KB leads to apoptosis in B cells.
We propose the following model for the mechanism of action of the fungal metabolite gliotoxin. By inhibiting activation of the transcription factor NF-KB, gliotoxin abrogates B and T cell stimulation, causing a severe immunosuppression. Furthermore, the inability to activate NF-KI3 may cause apoptosis of B cells, compounding the immunosuppressive effect. Our data suggest a direct role for gliotoxin in the pathology of Aspergillosis.
We thank Elmar Brhm for excellent technical assistance. This work was supported by grants from the Deutsche Forschungsgemeinschaft (Ba-957/1-3) and the European Community Biotechnology Programme to P.A. Baeuerle.
